Table 1.
Demographic characteristic of the patients according to the type of treatment
| All (n = 190) | Treatment |
p valuea | ||
|---|---|---|---|---|
| sorafenib (n = 51) | HAIC (n = 139) | |||
| Age | ||||
| Median, years | 69 | 69 | 69 | |
| ≥69 years | 101 (53.2) | 27 (52.9) | 74 (53.2) | 0.97 |
| Male | 156 (82.1) | 45 (88.2) | 111 (79.9) | 0.18 |
| ECOG performance status | ||||
| 0 | 175 (92.1) | 46 (90.2) | 129 (92.8) | 0.55 |
| 1–3 | 15 (7.9) | 5 (9.8) | 10 (7.2) | |
| Hepatitis B virus surface antigen | 52 (27.4) | 16 (31.4) | 36 (25.9) | 0.45 |
| Hepatitis C virus antibody | 99 (52.1) | 24 (47.1) | 75 (54.0) | 0.40 |
| Child-Pugh score | ||||
| 5 | 93 (48.9) | 28 (54.9) | 65 (46.8) | 0.32 |
| 6 | 97 (51.1) | 23 (45.1) | 74 (53.2) | |
| Branched-chain amino acid | 30 (15.8) | 9 (17.6) | 21 (15.1) | 0.67 |
| Maximum tumor size ≥50 mm | 59 (31.1) | 8 (15.7) | 51 (36.7) | 0.006 |
| Tumor number ≥6 | 133 (70.0) | 30 (58.8) | 103 (74.1) | 0.042 |
| Vascular invasion | 75 (39.5) | 18 (35.3) | 57 (41.0) | 0.48 |
| Extrahepatic spread | 49 (25.8) | 25 (49.0) | 24 (17.3) | <0.001 |
| AFP ≥400 ng/mL | 69 (36.3) | 16 (31.4) | 53 (38.1) | 0.39 |
| Crossover second-line chemotherapy | 50 (26.3) | 28 (54.9) | 22 (15.8) | <0.001 |
Data are presented as n (%). ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; HAIC, hepatic arterial infusion chemotherapy.
a
χ2 test.